NCT07637162
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
Enrolling by Invitation
PHASE3Ages 18+InterventionalTreatmentAxsome Therapeutics, Inc.
~300 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:AXS-14 (esreboxetine)
At a glance
Recruiting sites
0 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long-term Safety
Measured over Up to 52 weeks.
Conditions
Where it's being run
18 sites across 12 statesCalifornia3
Florida3
Georgia2
Tennessee2
Arkansas1
Illinois1
Kansas1
Kentucky1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participation in AXS-14-FM-301.
Exclusion
Unable to comply with study procedures.
Medically inappropriate for study participation in the opinion of the Investigator.
What this trial measures
- Long-term SafetyUp to 52 weeks.
Incidence of treatment-emergent adverse events following dosing with AXS-14